Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent clinical experience with dronabinol.

T F Plasse1, R W Gorter, S H Krasnow

  • 1UNIMED, Inc., Somerville, NJ 08876.

Pharmacology, Biochemistry, and Behavior
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications.

Expert opinion on investigational drugs·2023
Same author

Lawson Criterion for Ignition Exceeded in an Inertial Fusion Experiment.

Physical review letters·2022
Same author

IL-1α Modulates IFN-γ-Induced Production of CXCL9/MIG during Herpes Simplex Virus Type-1 Corneal Infection.

Current eye research·2020
Same author

International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery.

Anaesthesia·2019
Same author

Maternal factors and the risk of birth defects after IVF and ICSI: a whole of population cohort study.

BJOG : an international journal of obstetrics and gynaecology·2016

Dronabinol (delta-9-tetrahydrocannabinol) effectively manages chemotherapy-induced nausea and vomiting, potentially improving appetite and weight gain in HIV patients. Combining it with prochlorperazine may enhance efficacy and reduce side effects.

Area of Science:

  • Pharmacology
  • Oncology
  • Virology

Background:

  • Dronabinol (delta-9-tetrahydrocannabinol) is an established antiemetic for cancer chemotherapy patients.
  • Cannabinoids are being explored for broader therapeutic applications.

Purpose of the Study:

  • To evaluate the efficacy of dronabinol as an antiemetic and appetite stimulant.
  • To assess the safety and tolerability of dronabinol in patients with cancer and HIV.
  • To investigate the potential synergistic effects of dronabinol with prochlorperazine.

Main Methods:

  • Combination studies with prochlorperazine to measure antiemetic efficacy.
  • Open pilot studies to assess weight gain and appetite improvement in HIV patients.
  • Dose-ranging and tolerability assessments for chronic administration.

Related Experiment Videos

Main Results:

  • Dronabinol, in combination with prochlorperazine, enhanced antiemetic efficacy and reduced psychotropic side effects.
  • Dronabinol promoted weight gain in 70% of HIV-infected patients.
  • Improved appetite and good tolerability were observed in both cancer and HIV patient groups.

Conclusions:

  • Dronabinol is an effective antiemetic and appetite stimulant for cancer and HIV patients.
  • Combination therapy with prochlorperazine may optimize dronabinol's therapeutic profile.
  • Dronabinol demonstrates potential for chronic use in managing symptoms associated with these conditions.